Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV21 in Children and Adolescents With Sickle Cell Disease
NCT07247188Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of PCV21 in pneumococcal infection (2 arms), sponsored by Sanofi. Primary endpoints: Number of participants reporting immediate adverse events at 30 minutes, Number of participants reporting solicited injection site and solicited systemic reactions at 7 days and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
PCV21
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07247188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247188.